Skip to main content
OpenTrials
Completed

NCT Number: NCT02606201

Peri-sphincter Injection of Autologous Myofibres to Treat of Urinary Incontinence by Sphincter Deficiency

Stress urinary incontinence related to intrinsic sphincter deficiency (ISD) is a severe form of incontinence that may have a major impact on the quality of life. The main treatment is surgical and consists in the implantation of medical devices such as the artificial urinary sphincter, adjustable continence therapy, compressive sling, or injection of bulking agent.

The investigator has developed a new therapeutic strategy for ISD that consist to implant myofibers with their attached satellite cells (the main source of muscle progenitor cells) at the vicinity of the striated urethral sphincter. The principle of this method relies on the in vivo activation of satellite cells leading to the formation of regenerated myofibers (myotubes) generating a distinct and tonic muscular activity . The proof of concept was investigated in a Phase I clinical trial: Investigator found that the periurethral implantation of myofiber strips around the urethra generated an electromyographic activity improving urethral closure pressure in women with severe urinary incontinence associated to ISD. In this previous study, the technique of myofiber implantation was invasive, as it required a surgical approach and dissection of the urethra to place the myofiber. For the clinical trial IPSMA, the investigator sought to optimize the myofiber transplantation process using a method injection of myofibers core obtained by hydro-dissection. The injection technique is performed percutaneously under fluoroscopic and endoscopic control and does not require a surgical approach of the urethra.

This clinical trial is prospective, open-label, non-randomized, uncontrolled, single-center for the first stage and multicenter for the second stage, of 13 months for each patient aims to assess the efficacy and safety of IPSMA in the treatment of urinary incontinence in women with ISD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Urinary Incontinence by Intrinsic Sphincter Deficiency Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Lower Urinary Tract Symptoms Male Urogenital Diseases Pathological Conditions, Signs and Symptoms Signs and Symptoms Urinary Incontinence Urinary Incontinence, Stress Urination Disorders Urogenital Diseases Urologic Diseases Urological Manifestations

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Henri Mondor Hospital

Créteil, 94010, France

About this study

The investigator chose an assessment method in 2 stages according to the Simon plane . A total of 38 patients are needed. Assuming a ratio of 10% of lost patients or for which the primary endpoint was not evaluable, 4 additional patients will be included totaling 42 patients will be included.

This trial is single-center for the first stage and multicenter for the second stage.

11 patients will be included in the first stage and 31 patients in the second stage.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female.
  • Age> or = 18 years.
  • Patients with stress urinary incontinence by ISD for at least 6 months Failure of Pelvic floor muscle training (at least 20 sessions).
  • Fixed urethra : a negative Ulmsten test / Qtip test <30 °
  • 24h Pad test >50 g
  • Urodynamic criteria: LPP (leak points pressure) <100 cm H20 and MUCP <50 cm H2O replaced by Urodynamic criteria: MUCP <50 cm H2O (amendment n°3)
  • Collection of informed written consent

Exclusion criteria

  • Not affiliated to a social security scheme
  • Trouble hemostasis known
  • Untreated urinary tract infection
  • Muscle disease genetically determined or acquired
  • Patients with urinary incontinence by vesica-urethral hypermobility
  • Incomplete bladder emptying: post void residual> 20% of the volume voided during urination> 150cc
  • Maximum urinary flow rate <12 ml / sec replaced by maximum urinary flow rate <12 ml / sec for volume urinated during urination > 150cc (amendment n°3)
  • overactive bladder
  • Bladder capacity (B3) <200 cc (deleted in amendment n°3)
  • Urethral stricture
  • Anticoagulant therapy that cannot be replaced by a low molecular weight heparin
  • Pregnant or intend to become pregnant during the study period or breastfeeding informed by the patient during the consultation.

Treatment and study plan

Peri sphincter injection Autologous myofibers

Other

The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.

All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.

During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control.

Primary outcomes

  1. Step 1: Tolerance

    Time frame: One year after treatment

    • Tolerance: Serious adverse events grade 3 or more related to the procedure according to Data Safety and Monitoring Board (DSMB)

  2. Step 1 and 2: Rate of patients responder at M12 after surgery

    Time frame: One year after treatment

    Efficiency: Response is defined by an improvement in 24h pad weight as greater than 50% reduction from baseline and improvement in the number of incontinence episodes per day as greater than 50% reduction from baseline

Secondary outcomes

  1. Occurrence of serious and non-serious adverse events

    Time frame: One year after treatment

  2. Proportion of patients cured at M12. patients are considered as cured if: - The absence of pad use, a 24h pad test <2g AND - The absence of urinary leakage reported in the voiding diary (3 consecutive days).

    Time frame: One year after treatment

  3. Improvement of quality of life

    Time frame: One year after treatment

  4. Response times

    Time frame: One year after treatment

  5. Urodynamic evaluation

    Time frame: One year after treatment

    Leak Point Pressure (LPP), maximal urethral closure pressure (MUCP), area under the curve (profilometry), electromyogram (EMG) gives urodynamic evaluation

  6. Number of re-intervention required (conventional treatment after 6 months) to treat persistent urinary incontinence after IPSMA

    Time frame: 6 months after treatment

  7. Patients with a reduction in the 24h pad test <50% at one year will be considered failure.

    Time frame: One year after treatment

  8. Direct global cost of IPSMA surgery

    Time frame: One year after treatment

  9. Healing times

    Time frame: One year after treatment

    Defined by :

    • The absence of pad use, a 24h pad test <2g AND
    • The absence of urinary leakage reported in the voiding diary (3 consecutive days).

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Acronym: IPSMA

Important dates

Study start
2016
Primary completion
2021
Study completion
2021
First posted
Nov 17, 2015
Registry last updated
May 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.